Sugammadex

Generic Name: Sugammadex

Brand Names: Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal

Drug Type: Small Molecule

Chemical Formula: C_₇₂H_₁₁₂O_₄₈S_₈

CAS Number: 343306-71-8

Unique Ingredient Identifier: 361LPM2T56

Background: Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

Indication: Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.

Associated Conditions: Neuromuscular blockade caused by vecuronium bromide

Associated Therapies: -

Clinical Trials

Functional Respiratory Imaging After Neostigmine or Sugammadex

Phase 4

Completed

Conditions: Respiratory-Gated Imaging Techniques

Interventions: Drug: Sugammadex
Drug: Neostigmine
Drug: Water for injection

First Posted Date: 2014-11-06

Last Posted Date: 2015-04-21

Lead Sponsor: Onze Lieve Vrouw Hospital

Target Recruit Count: 13

Registration Number: NCT02284412

Locations: 🇧🇪
OLV Hospital, Aalst, Belgium

A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia

Phase 4

Terminated

Conditions: Neuromuscular Blockade

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2014-10-03

Last Posted Date: 2021-06-16

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 70

Registration Number: NCT02256280

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Mi, Italy

Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile

Phase 4

Completed

Conditions: Postoperative Respiratory Condition

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2014-09-18

Last Posted Date: 2017-02-06

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 100

Registration Number: NCT02243943

Locations: 🇳🇱
Leiden Medical University, Leiden, Zuid Holland, Netherlands

Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade

Phase 4

Completed

Conditions: Intraocular Pressure Changes During Tracheal Extubation

Interventions: Drug: sugammadex
Drug: neostigmine+atropine

First Posted Date: 2014-08-13

Last Posted Date: 2015-04-21

Lead Sponsor: T.C. ORDU ÜNİVERSİTESİ

Target Recruit Count: 36

Registration Number: NCT02215382

Locations: 🇹🇷
Anesthesiology and Reanimation Dept. Ordu University Training and Research Hospital, Altınordu, Ordu, Turkey

Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea

Phase 4

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2014-06-10

Last Posted Date: 2014-12-09

Lead Sponsor: Diskapi Teaching and Research Hospital

Target Recruit Count: 74

Registration Number: NCT02160223

Locations: 🇹🇷
Diskapi Yildirim Beyazit Teaching and Research Hospital, Ankara, Turkey

A Pilot Study Using Rocuronium to Prevent Intermediate Syndrome After Organophosphorus Insecticide Poisoning

Phase 2

Completed

Conditions: Organophosphate Poisoning

Interventions: Drug: Rocuronium
Drug: Sugammadex

First Posted Date: 2014-05-26

Last Posted Date: 2016-11-17

Lead Sponsor: University of Edinburgh

Target Recruit Count: 45

Registration Number: NCT02147054

Locations: 🇱🇰
Peradeniya Teaching Hospital, Peradeniya, Central Province, Sri Lanka

The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

Not Applicable

Completed

Conditions: Robot-Assisted Laparoscopic Radical Prostatectomy

Interventions: Procedure: deep neuromuscular blockade
Procedure: moderate neuromuscular blockade
Drug: Rocuronium
Drug: Atracurium
Drug: Sugammadex
Drug: Neostigmine